Autologous cytokine-induced killer cells combined with chemotherapy in the treatment of advanced colorectal cancer: a randomized control study

Du, Chunyang; Liu, Zhaozhe; Ding, Zhenyu; Guo, Fang; Ma, Dongchu; Xie, Xiaodong

doi:10.1007/s10330-013-1214-y

Cited by 9 publications

(24 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This regimen was repeated every 2 weeks. To receive chemotherapy, patients were required to have adequate kidney, liver, and bone marrow function [ 17 – 20 ].…”

Section: Methodsmentioning

confidence: 99%

Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer

Niu

Ren

Zhang

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Purpose. This retrospective study determined the delayed-type hypersensitivity (DTH) skin test and safety of dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell immunotherapy and the survival compared to chemotherapy in 239 colorectal cancer (CRC) patients. Methods. DTH and safety of the immunotherapy were recorded. The overall survival (OS) and disease free survival curves were compared according to the immunotherapy and/or chemotherapy received with Kaplan-Meier estimates. Results. Of the 70 patients who received immunotherapy, 62.86% had a positive DTH skin test, 38.57% developed fever, 47.14% developed insomnia, 38.57% developed anorexia, 4.29% developed joint soreness, and 11.43% developed skin rash. For 204 resectable CRC patients, median survival time (MST) (198.00 days) was significantly longer in patients with immunotherapy plus chemotherapy than with chemotherapy alone (106.00 days) (P = 0.02). For 35 patients with unresectable or postsurgery relapsed CRC and who were confirmed to be dead, no statistical difference was observed in the MST between the patients treated with immunotherapy and with chemotherapy (P = 0.41). MST in the patients treated with chemotherapy plus immunotherapy was 154 days longer than that of patients treated with chemotherapy alone (P = 0.41). Conclusions. DC vaccination and CIK immunotherapy did not cause severe adverse effects, induce immune response against CRC, and prolong OS.

show abstract

“…This regimen was repeated every 2 weeks. To receive chemotherapy, patients were required to have adequate kidney, liver, and bone marrow function [ 17 – 20 ].…”

Section: Methodsmentioning

confidence: 99%

Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer

Niu

Ren

Zhang

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Through patients in all study arms receiving CIK therapy; and patients in the control arm being healthy subjects. Thus, 70 studies containing 16 English 17,19,[25][26][27][28][29][30][31][32][33][34][35][36][37][38] and 44 Chinese 24,39-91 language articles were selected for study synthesis (Figure 1).…”

Section: Search Resultsmentioning

confidence: 99%

“…All studies were single-centre studies performed in mainland China. Fifty-four studies [24][25][26]29,32,35,36,[39][40][41][42][44][45][46][47][48][49][50][51][52][53]55,[57][58][59][60][61][62][63][65][66][67][68][69][70][71][72][73][74][75]77,78,[80][81][82][83][85][86][87][88][89][90]…”

Section: Study and Patient Characteristicsmentioning

confidence: 99%

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis

Tomita

Dhakal

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The number of clinical studies evaluating the benefit of cytokine-induced killer cell (CIK) therapy, an adoptive immunotherapy, for colorectal cancer (CRC) are increasing. In many of these trials CIK therapy was co-administered with conventional cancer therapy. The aim of this review is to systematically assess the available literature, in which the majority were only in Chinese, on CIK therapy for the management of CRC using meta-analysis, and to identify parameters associated with successful CIK therapy implementation. Methods: Prospective and retrospective clinical studies which compared CIK therapy to non-CIK therapy in CRC patients were searched for electronically on MEDLINE, Embase, CNKI and Wanfang Data databases. The clinical endpoints of overall survival (OS), progression-free survival (PFS), OS and PFS rates, overall response rate (ORR) and toxicity were meta-analysed using hazard (HR) and relative ratios (RR), and subgroup analyses were performed using Chi-square (Chi2) test and I-square (I2) statistics for study design, disease stage, co-therapy type, and timing of administration. Results: In total, 70 studies involving 6,743 patients were analysed. CIK therapy was favoured over non-CIK therapy for OS (HR=0.59, 95% CI: 0.53-0.65), PFS (HR=0.55, 95% CI: 0.47-0.63), and ORR (RR=0.65, 95% CI: 0.57-0.74) without increasing toxicity (HR=0.59, 95% CI 0.16-2.25). Subgroup analyses on OS and PFS by study design (randomised versus non-randomised study design), disease stage (Stage I-III versus Stage IV), co-treatment with dendritic cells (CIK versus DC-CIK therapy), or timing of therapy administration (concurrent versus sequential with co-administered anti-cancer therapy) also showed that the clinical benefit of CIK therapy was robust in any subgroup analysis. Furthermore, co-treatment with dendritic cells did not improve clinical outcomes over CIK therapy alone. Conclusions: Compared with standard therapy, patients who received additional CIK cell therapy had favourable outcomes without increased toxicity, warranting further investigation into CIK therapy for the treatment of CRC.

show abstract

“…Through assessment of the quality of life, it was demonstrated that patients receiving CIK in addition to chemotherapy had significantly improved physical function, overall health status, and fewer symptoms. Regarding side effects, CIK did not cause any severe toxicity among patients [ 65 ].…”

Section: Clinical Studies On Cik Cell Therapymentioning

confidence: 99%

“…CIK cycles were at least 4 weeks apart Variable chemotherapy regimens (Oxaliplatin + Fluorouracil, or Irinotecan + 5-FU, or 5-FU, or Other) There was no significant difference between two groups in OS. The DFS was statistically prolonged in the CIK group No immediate reaction to CIK cell transfusion Du [ 65 ] 2013 IV Randomized control study 10.5 30 30 XELOX chemotherapy + 5*10 9 CIK cells in one hour every other day for 3 times after each cycle of chemotherapy XELOX chemotherapy ORRs (CR + PR) were 12/30 and 11/30 in the study and control group, respectively ( P = 0.791). The DCRs (CR + PR + SD) were 26/30 and 17/30 in the study and control group, respectively, which were significantly different ( P = 0.010) PFSs were 10.15 and 8.64 months in the study and control group, respectively Temporary fever, mild to moderate fatigue, and joint pain in the study group Niu [ 66 ] 2014 II, III Retrospective comparative study 16.3 74 130 IV infusion of 1*10 7 DC cells on days 8, 15, and 22 and intradermal injection on days 29, 36, and 43 + IV infusion of 1*10 9 CIK cells on days 11 to 14 + Capecitabine; or Capecitabine plus Oxaliplatin; or Oxaliplatin, Leucovorin, and 5-FU Capecitabine; or Capecitabine plus Oxaliplatin; or Oxaliplatin, Leucovorin, and 5-FU MSTs in the study and control groups were 198 and 106 days, respectively, which was longer in the study group ( P = 0.02) DTH, fever, insomnia, anorexia, joint soreness, skin rash were observed in DC-CIK groups IV NA 7 (group I) / 17 (group I + C) 11 (group C) MSTs in the I, I + C, and C groups were 249, 264, and 110 days, respectively.…”

Section: Clinical Studies On Cik Cell Therapymentioning

confidence: 99%

Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer

2022

View full text Add to dashboard Cite

Cytokine-induced killer (CIK) cell therapy is a type of adoptive immunotherapy that due to its high proliferation rate and anti-tumor characteristics, is being investigated to treat various solid tumors. Since advanced colorectal cancer (CRC) has high mortality and poor survival rates, and the efficacy of chemotherapy and radiotherapy is limited in treatment, the application of CIK cell therapy in CRC has been evaluated in numerous studies. This review aims to summarize the clinical studies that investigated the safety and clinical efficacy of CIK cell therapy in CRC. Therefore, 1,969 enrolled CRC patients in the clinical trials, of which 842 patients received CIK cells in combination with chemotherapy with or without dendritic cell (DC) infusions, were included in the present review. Furthermore, the signaling pathways involved in CIK cell therapy and novel methods for improving migration abilities are discussed.

show abstract

Autologous cytokine-induced killer cells combined with chemotherapy in the treatment of advanced colorectal cancer: a randomized control study

Cited by 9 publications

References 11 publications

Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer

Retrospective Comparative Study of the Effects of Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Immunotherapy with that of Chemotherapy Alone and in Combination for Colorectal Cancer

Use of cytokine-induced killer cell therapy in colorectal cancer patients: a systematic review and meta-analysis

Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer

Contact Info

Product

Resources

About